Russian TB mRNA vaccine successfully passed preclinical trials

Scientists at the Scientific Center for Translational Medicine at Sirius University have successfully developed an RNA-based vaccine against tuberculosis. The vaccine has shown promising results in preclinical trials, demonstrating high immunogenicity and protective activity when administered to rodents.
“A dossier has been prepared for the first phase of clinical trials,” the statement says. The project is being implemented with the backing of the Ministry of Education and Science of the Russian Federation. According to the researchers, mRNA-based drugs are delivered to target organs using lipid nanoparticles. This allows ribonucleic acid to be used to develop vaccines and cancer treatments.
According to Roman Ivanov, the director of the Scientific Center, the BCG vaccine is currently the only approved vaccine for preventing tuberculosis. However, its effectiveness in providing full protection against pulmonary tuberculosis in adults is limited.